Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?

Lupus

Volumn 18, Issue 1, 2009, Pages 53-60

  Rotar, Z ^a   Rozman, B ^a   De Groot, P G ^b   Sanmarco, M ^c   Shoenfeld, Y ^d   Meroni, P L ^e   Cervera, R ^f   Pengo, V ^g   Cimaz, R ^h   Avcin T ^a   Carp, H J A ⁱ   Tincani, A ^j  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HÔPITAL DE LA CONCEPTION   (France)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF MILAN   (Italy)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Hughes syndrome

Indexed keywords

CARDIOLIPIN ANTIBODY;

ANIMAL; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MODEL; HUMAN; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; RISK FACTORS;

EID: 62749204448     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308097569     Document Type: Article

References (64)

1. Eschwège, V, Darnige, L, Piette, JC, Boffa, MC. European forum on antiphospholipid antibodies: report on the first meeting, 10-11 October 1997, Hôpital Saint-Louis, Paris. Lupus 1998; 7: 439-444.
2. Cervera, R, Font, J, Tincani, A, Boffa, M. V meeting of the European forum on antiphospholipid antibodies. Autoimmun Rev 2006; 5: 499-507.
3. Hughes, GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287: 1088-1089.
4. Shoenfeld, Y, Meroni, PL, Cervera, R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 2008; 67: 438-442.
5. Pierangeli, SS, Vega-Ostertag, ME, Raschi, E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007; 66: 1327-1333.
6. Tincani, A. Immunological abnormalities in the antiphospholipid syndrome. In: Asherson, R, Cervera, R, Piette, J, Shoenfeld, Y, (eds), The antiphospholipid syndrome ii: autoimmune thrombosis. Amsterdam, Elsevier; 2002. p. 271-284.
7. Andreoli, L, Pregnolato, F, Burlingame, RW, et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun 2008; 30: 51-57.
8. Alarcón-Riquelme, ME. The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. Springer Semin Immunopathol 2006; 28: 109-117.
9. Blank, M, Krause, I, Fridkin, M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.
10. Berlin, T, Zandman-Goddard, G, Blank, M, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci 2007; 1108: 584-593.
11. Arnson, Y, Amital, H, Shoenfeld, Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137-1142.
12. Meroni, PL, di Simone, N, Testoni, C, D'Asta, M, Acaia, B, Caruso, A. Antiphospholipid antibodies as cause of pregnancy loss. Lupus 2004; 13: 649-652.
13. Di Simone, N, Meroni, PL, D'Asta, M, DiNicuolo, F, D'Alessio, MC, Caruso, A. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 2007; 13: 189-196.
14. Holers, VM, Girardi, G, Mo, L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220.
15. Girardi, G, Berman, J, Redecha, P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-1654.
16. Girardi, G, Redecha, P, Salmon, JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
17. Berman, J, Girardi, G, Salmon, JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-490.
18. Martinez de la Torre, Y, Buracchi, C, Borroni, EM, et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007; 104: 2319-2324.
19. Stone, S, Pijnenborg, R, Vercruysse, L, et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006; 27: 457-467.
20. Shamonki, JM, Salmon, JE, Hyjek, E, Baergen, RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167.e1-167.e5.
21. Cavazzana, I, Nebuloni, M, Cetin, I, et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process. J Autoimmun 2007; 28: 160-164.
22. de Laat, B, Derksen, RHWM, Urbanus, RT, de Groot, PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-1545.
23. Iverson, GM, Victoria, EJ, Marquis, DM. Anti-beta2 glycoprotein I (beta2-GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95: 15542-15546.
24. Ioannou, Y, Pericleous, C, Giles, I, Latchman, DS, Isenberg, DA, Rahman, A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-290.
25. de Laat, B, Derksen, RHWM, van Lummel, M, Pennings, MTT, de Groot, PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-1924.
26. Sherer, Y, Shoenfeld, Y. Atherosclerosis. Ann Rheum Dis 2002; 61: 97-99.
27. Doria, A, Shoenfeld, Y, Wu, R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-1077.
28. Ames, PRJ, Margarita, A, Sokoll, KB, Weston, M, Brancaccio, V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64: 315-317.
29. Matsuura, E, Kobayashi, K, Inoue, K, Lopez, LR, Shoenfeld, Y. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005; 14: 736-741.
30. Roman, MJ, Shanker, B, Davis, A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
31. Cervera, R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501-507.
32. Amigo, MC, García-Torres, R. Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis. Curr Rheumatol Rep 2000; 2: 262-270.
33. Ziporen, L, Goldberg, I, Arad, M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996; 5: 196-205.
34. Cucnik, S, Kveder, T, Krizaj, I, Rozman, B, Bozic, B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004; 63: 1478-1482.
35. Hughes, GRV, Khamashta, MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 1127.
36. Sorice, M, Griggi, T, Circella, A, et al. Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates. J Immunol Methods 1994; 173: 49-54.
37. Cervera, R, Bucciarelli, S, Espinosa, G, et al. Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry" -a tribute to the late Josep Font. Ann N Y Acad Sci 2007; 1108: 448-456.
38. Cervera, R, Espinosa, G, Bucciarelli, S, Gómez-Puerta, JA, Font, J. Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev 2006; 6: 81-84.
39. Lyden, TW, Vogt, E, Ng, AK, Johnson, PM, Rote, NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol 1992; 22: 1-14.
40. Shurtz-Swirski, R, Inbar, O, Blank, M, Cohen, J, Bakimer, R, Shoenfeld, Y. In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy. Am J Reprod Immunol 1993; 29: 206-210.
41. Di Simone, N, Meroni, PL, de Papa, N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43: 140-150.
42. Quenby, S, Mountfield, S, Cartwright, JE, Whitley, GS, Chamley, L, Vince, G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005; 83: 691-698.
43. Kaider, AS, Kaider, BD, Janowicz, PB, Roussev, RG. Immunodiagnostic evaluation in women with reproductive failure. Am J Reprod Immunol 1999; 42: 335-346.
44. Egbase, PE, Al Sharhan, M, Diejomaoh, M, Grudzinskas, JG. Antiphospholipid antibodies in infertile couples with two consecutive miscarriages after in-vitro fertilization and embryo transfer. Hum Reprod 1999; 14: 1483-1486.
45. Sher, G, Fisch, JD, Maassarani, G, Matzner, W, Ching, W, Chong, P. Antibodies to phosphatidylethanolamine and phosphatidylserine are associated with increased natural killer cell activity in non-male factor infertility patients. Hum Reprod 2000; 15: 1932-1936.
46. Carp, H, Toder, V, Aviram, A, Daniely, M, Mashiach, S, Barkai, G. Karyotype of the abortus in recurrent miscarriage. Fertil Steril 2001; 75: 678-682.
47. Philipp, T, Philipp, K, Reiner, A, Beer, F, Kalousek, DK. Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. Hum Reprod 2003; 18: 1724-1732.
48. Takakuwa, K, Asano, K, Arakawa, M, Yasuda, M, Hasegawa, I, Tanaka, K. Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody. Fertil Steril 1997; 68: 54-58.
49. Ogasawara, M, Aoki, K, Okada, S, Suzumori, K. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril 2000; 73: 300-304.
50. Ulcova-Gallova, Z, Krauz, V, Novakova, P, et al. Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol 2005; 54: 112-117.
51. Boffa, M, Lachassinne, E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus 2007; 16: 634-641.
52. McAllister, DL, Kaplan, BJ, Edworthy, SM, et al. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J Int Neuropsychol Soc 1997; 3: 370-376.
53. Ross, G, Sammaritano, L, Nass, R, Lockshin, M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 2003; 157: 397-402.
54. Neri, F, Chimini, L, Bonomi, F, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 2004; 13: 805-811.
55. Nacinovich, R, Galli, J, Bomba, M, et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum 2008; 59: 345-351.
56. Levy, M, Montes De Oca, M, Babron, MC. [Incidence of lupus erythematosus disseminatus in children in Parisian region] Presse Med 1989; 18: 2022.
57. Avcin, T, Benseler, SM, Tyrrell, PN, Cucnik, S, Silverman, ED. A follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 206-213.
58. Brunner, HI, Silverman, ED, To, T, Bombardier, C, Feldman, BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-444.
59. Ravelli, A, Caporali, R, Di Fuccia, G, Zonta, L, Montecucco, C, Martini, A. Anticardiolipin antibodies in pediatric systemic lupus erythematosus. Arch Pediatr Adolesc Med 1994; 148: 398-402.
60. Levy, M, de Oca, MM, Wechsler, B. [Systemic lupus erythematosus of paediatric onset: long-term follow-up of a cohort including 104 patients (1975-1985)] Arch Pediatr 2004; 11: 503-506.
61. Campos, LMA, Kiss, MH, D'Amico, EA, Silva, CAA. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 2003; 12: 820-826.
62. Descloux, E, Durieu, I, Cochat, P, et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford) 2008; 47: 183-187.
63. Avcin, T, Silverman, ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus 2007; 16: 627-633.
64. Avcin, T, Cimaz, R, Meroni, PL. Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in the paediatric population. Lupus 2001; 10: 897-898.